SK Biopharmaceutical’s $800.1 Million Initial Public Offering

SK Biopharmaceuticals Co., Ltd. (“SK Biopharmaceuticals”), as issuer, and SK Holdings Co., Ltd. (“SK Holdings”), as selling shareholder, on the deal. SK Biopharmaceuticals completed its initial…